Abstract
The care of beta-thalassemia has improved dramatically over the last few decades mostly because of: i) improved blood transfusion regimens; ii) wide-spread use of deferoxamine; iii) surgical advances; and iv) allogeneic hematopoietic stem cell transplantation. Advanced healthcare standards, improved life expectancy, and complications specific to beta-thalassemia necessitate a renewed approach to the pulmonary issues of this disease.
While transfusion-related infections are expected, and Streptococcal, Staphylococcal, E. coli and Salmonella infections are common, a number of special problems are also reported. Mycoplasma pneumoniae infections associated with hemolytic anemia, Pneumocystis carinii pneumonia and necrotizing pneumonia caused by Klebsiella pneumoniae are indicative of the special susceptibility to infections in beta-thalassemia. The issue of immune function in the (non-transplanted) patient with thalassemia is brought up. Conditions associated with chronic airway inflammation, such as plastic bronchitis and allergic bronchopulmonary mycosis, are discussed as well as life-threatening complications. In an attempt to organize the diagnostic approach to pulmonary disease in beta-thalassemia, four working entities are delineated, which, almost invariably, tend to overlap and aggravate each other: i) disorders inherent to the beta-thalassemia hemoglobinopathy; ii) chronic lung disease and its complications; iii) immunological corollaries of the therapy of beta-thalassemia, i.e. chronic transfusion, splenectomy and bone marrow transplantation; and iv) airway inflammation.Keywords: Beta-thalassemia, pulmonary, tranfusion.
Graphical Abstract
Current Respiratory Medicine Reviews
Title:Pulmonary Disease in Beta-Thalassemia
Volume: 12 Issue: 4
Author(s): Demetrios S. Theodoropoulos and Maria S. Theodoropoulou
Affiliation:
Keywords: Beta-thalassemia, pulmonary, tranfusion.
Abstract: The care of beta-thalassemia has improved dramatically over the last few decades mostly because of: i) improved blood transfusion regimens; ii) wide-spread use of deferoxamine; iii) surgical advances; and iv) allogeneic hematopoietic stem cell transplantation. Advanced healthcare standards, improved life expectancy, and complications specific to beta-thalassemia necessitate a renewed approach to the pulmonary issues of this disease.
While transfusion-related infections are expected, and Streptococcal, Staphylococcal, E. coli and Salmonella infections are common, a number of special problems are also reported. Mycoplasma pneumoniae infections associated with hemolytic anemia, Pneumocystis carinii pneumonia and necrotizing pneumonia caused by Klebsiella pneumoniae are indicative of the special susceptibility to infections in beta-thalassemia. The issue of immune function in the (non-transplanted) patient with thalassemia is brought up. Conditions associated with chronic airway inflammation, such as plastic bronchitis and allergic bronchopulmonary mycosis, are discussed as well as life-threatening complications. In an attempt to organize the diagnostic approach to pulmonary disease in beta-thalassemia, four working entities are delineated, which, almost invariably, tend to overlap and aggravate each other: i) disorders inherent to the beta-thalassemia hemoglobinopathy; ii) chronic lung disease and its complications; iii) immunological corollaries of the therapy of beta-thalassemia, i.e. chronic transfusion, splenectomy and bone marrow transplantation; and iv) airway inflammation.Export Options
About this article
Cite this article as:
Theodoropoulos S. Demetrios and Theodoropoulou S. Maria, Pulmonary Disease in Beta-Thalassemia, Current Respiratory Medicine Reviews 2016; 12 (4) . https://dx.doi.org/10.2174/1573398X13666161221150247
DOI https://dx.doi.org/10.2174/1573398X13666161221150247 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews The Entirely Subcutaneous Defibrillator (S-Icd): State of the Art and Selection of the Ideal Candidate
Current Cardiology Reviews The Pathophysiology of Sleep Apnoea: What We have Learned from Animal Models of Chronic Intermittent Hypoxia
Current Respiratory Medicine Reviews Current and Future Approaches to the Prevention and Treatment of Staphylococcal Medical Device-Related Infections
Current Pharmaceutical Design Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Emergence of Multi-Drug Resistance Gram-Positive Bacteria and New Active Antibiotics
Current Medicinal Chemistry - Anti-Infective Agents Receptor Binding Ligands to Image Infection
Current Pharmaceutical Design Antimicrobial Drug Interactions in the Critically Ill Patients
Current Clinical Pharmacology A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Nucleotide Second Messenger Signaling as a Target for the Control of Bacterial Biofilm Formation
Current Topics in Medicinal Chemistry <i>Corynebacterium Striatum</i>, an Emerging Nosocomial Pathogen: Case Reports
Infectious Disorders - Drug Targets Evaluation of <sup>99m</sup>Technetium-Vancomycin Imaging Potential in Experimental Rat Model for the Diagnosis of Infective Endocarditis
Current Medical Imaging High-Level Aminoglycoside Resistance in Enterococcus Faecalis and Enterococcus Faecium; as a Serious Threat in Hospitals
Infectious Disorders - Drug Targets Macrolides Allergy
Current Pharmaceutical Design Hydroxychloroquine Sulfate (Plaquenil): A Possible Candidate for Pandemic SARS-CoV-2 or (COVID-19) ?
Coronaviruses Proteomics Analysis: A Powerful Tool to Identify Proteome Phenotype and Proteome Signature in Enterococcus faecalis
Current Proteomics Anti-Pathogenic Efficacy and Molecular Targets of a Polyherbal Wound- Care Formulation (Herboheal) Against Staphylococcus aureus
Infectious Disorders - Drug Targets Brucella Pneumonia with Systemic Complications and Pancytopenia: A Case Report
Infectious Disorders - Drug Targets Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial Applications
Recent Patents on Biotechnology Registered and Investigational Drugs for the Treatment of Methicillin-Resistant Staphylococcus aureus Infection
Recent Patents on Anti-Infective Drug Discovery